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Abstract The synthesis of Na-protected N,N0,N00-trisub-
stituted guanidinopeptide mimic molecules suitably deco-
rated in peptide backbone has been delineated in one pot
employing HgCl2 as a desulphurizing agent. Chiral N
a-
protected thioureidopeptide esters were employed as syn-
thons for the synthesis of title molecules. The protocol is
simple and the reaction conditions employed were mild,
amenable to the amino acid chemistry.
Keywords Thioureidopeptide  HgCl2 
Desulphurization  N,N0,N00-trisubstituted guanidinopeptide
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Introduction
Guanidine functionality is widespread in many natural and
synthetic biologically active molecules. Arginine rich
peptide sequences such as HIV-1 TAT and penetratin are
known to possess cell membrane translocating properties
(Jadhav et al. 1998; Pepinsky et al. 1994). Guanidine head
group of arginine is responsible for protein enzyme ion
pairing, nitric oxide synthesis and insulin sensitivity
(Zhang et al. 1997; Fast et al. 1997). The low bioavail-
ability and cell membrane permeability of peptides limit
their wider utility as tools in molecular biology. Many
different types of unnatural biomimetics have been studied,
of which backbone modified guanidine tethered pep-
tidomimetics is one of the subjects of our current interest
(Farmer 1980; Spatola 1983; Lam et al.1997; Ahn et al.
2002). Since the alkyl substituted guanidines are present in
natural products and arginine containing peptide systems
(Berlinck and Kossuga 2005; Berlinck et al. 2008; Heys
et al. 2000), methods for the synthesis of guanidines with
multiple substitution patterns are desirable.
Synthesis of substituted guanidines has been investi-
gated both in solid phase and in solution phase. Detailed
literature survey revealed several synthetic entries into
substituted guanidine systems. These transformations
include the reaction of alkyl or aryl guanidines with various
electrophiles under basic conditions (Augstein et al. 1965;
Stahle et al. 1980). Others involve the reaction of elec-
trophilic precursor of guanidine moiety with a primary or
secondary amine. Electrophilic imino centres generated
from urea or thiourea and carbodiimide obtained by the
dehydration or desulphurization of urea or thiourea
respectively serve as suitable starting materials for the
synthesis of trisubstituted guanidines (Barton et al. 1982;
Barvian et al. 1997). In many of the above mentioned
reactions, thiourea was employed as one of the precursors
in the presence of EDCl, Sanger’s reagent, Mukaiyama
reagent, HgCl2 to afford trisubstituted guanidines (Jeffer-
son et al. 2004; Li et al. 2003). However, the most widely
used method involves the addition of nucleophilic amine to
the in situ generated active carbodiimide from the corre-
sponding thiourea (Kurzer and Douraghi-Zadeh 1967;
Shibaruma et al. 1977; Kim and Yi 1986a, b; Isobe and
Ishikawa 1999). For the generation of carbodiimide from
thiourea, heavy metal thiophiles such as Hg salt have been
employed to effect the transformation (Li et al. 2002;
Dudic et al. 2004; Luo et al. 2008). Guanylation of thiourea
using HgCl2 has long been reported in the literature and
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thus widely used protocol for guanylation reaction, as the
work up procedure was simple. Also the yield was rela-
tively promising.
The guanidine chemistry has not been much explored in
the context of peptidomimetics except for the arginine
analogs (Feichtinger et al. 1998a, b; Zapf et al. 2001;
Schade et al. 2008; Martin et al. 2008; Balakrishnan et al.
2007). Recently Suhs and Konig (2006) reported the syn-
thesis of functionalized guanidino amino acids which were
structurally related to Arg and resembled a dipeptide hav-
ing a- and c-amino acid with a guanidinium group in the
main chain. (Zhang et al. 2003; Zhang and Fan 2005)
developed a strategy for the preparation of N,N’-bridged
oligomeric guanidines bearing peptide side chains. Tri-
functional amino acids and the corresponding peptides
pose some limitations which otherwise will be useful if
properly utilized by employing them as suitable synthons.
In continuation of our interest in synthesizing variety of
backbone modified peptide surrogates such as ureidopep-
tides, thioureidopeptides, dithiocarbamate, trithiocarbon-
ate, and heterocycles (Patil et al. 2003; Sureshbabu et al.
2009), we sought to synthesize another surrogate i.e,
guanidinopeptide mimics. We envisaged that N-protected
thioureidopeptides can be useful synthons for Na-protected
N,N0,N00-trisubstituted guanidinopeptide mimics via desul-
phurization employing HgCl2.
Experimental
Materials and Methods
All solvents were freshly distilled before use. Amino acids
were used as received from Sigma-Aldrich Company. 1H
and 13C NMR spectra were recorded on a Bruker AMX
300 MHz and 75 MHz respectively, with DMSO-d6 as an
internal standard. Mass spectra were recorded using high
resolution mass spectrometer (HRMS) Q-T of mass spec-
trometer and the samples were dried under vacuum before
analysis. All the reactions were monitored using TLCs with
precoated silica gel plates purchased from Merck. Chiral
HPLC analysis of isomers was carried out by Agilent 1100
series, Lux 5u Amylose-2, 250 9 4.60 mm.
Typical Procedure for the Preparation
of Trisubstituted Guanidinopeptides (2a–k)
The starting thioureidopeptide (1.0 mmol) and amine
(1.2 mmol) were dissolved in dimethylformamide (5 mL/
mmol) at room temperature. The mixture was then charged
with triethylamine (2.2 mmol) and cooled in an ice bath.
Mercuric chloride (0.35 mmol) was then added at 0 C and
the mixture was stirred for 20 min before it was warmed to
room temperature. When the reaction was completed as
monitored through TLC, the reaction mixture was diluted
with ethyl acetate (10 mL) and filtered through Celite. The
Celite cake was then washed with additional ethyl acetate
(5 mL). The filtrate was washed with water, then with brine
and the organic layer was dried over anhydrous Na2SO4
and evaporated in vacuo under reduced pressure. The crude
product thus obtained was further purified on a silica gel
column (EtOAc: Hexane).
Spectroscopic Data of Compounds 2a–j
(2S, 3R)-Methyl-2-(3-((S)-2-(((9H-fluoren-9-
yl)methoxy)carbonyl)propyl)-2-phenylguanidino)-3-
methylpentanoate (2a) 330 mg
1H NMR (300 MHz, CDCl3) d 0.94 (t, J = 4.2 Hz, 3H),
0.99 (d, J = 4.6 Hz, 3H), 1.24–1.30 (m, 2H), 1.29 (d,
J = 6.8 Hz, 3H), 2.04–2.07 (m, 1H), 2.94–3.03 (m, 2H),
3.71 (s, 3H), 4.02–4.07 (m, 1H), 4.42 (t, J = 6.1 Hz, 1H),
4.62 (d, J = 7.1 Hz, 2H), 4.89–4.93 (m, 1H), 5.41 (br s,
1H), 6.12 (br s, 1H), 6.73 (br, 1H), 7.10–7.75 (m, 13H); 13C
NMR (75 MHz, CDCl3) d 10.4, 16.3, 18.9, 28.6, 35.0,
42.4, 46.4, 48.2, 50.6, 52.3, 66.4, 120.6, 125.4, 125.8,
127.4, 127.6, 128.4, 128.8, 139.1, 141.0, 143.2, 155.2,
155.9, 172.1; HRMS calcd for C32H38N4O4 m/z 565.1796
(M??Na), found 565.1702.
(S,E)-Methyl-2-(3-(2-(((9H-fluoren-9-
yl)methoxy)carbonyl)ethyl)-2-m-tolylguanidino)-3-
phenylpropanoate (2b) 380 mg
1H NMR (300 MHz, CDCl3) d 2.32 (s, 3H), 2.95–3.03 (m,
2H), 3.12–3.24 (m, 4H), 3.67 (s, 3H), 3.77–3.82 (m, 1H),
4.12–4.28 (m, 1H), 4.66 (d, J = 5.6 Hz, 2H), 5.17 (br s,
1H), 6.18 (br s, 1H), 6.54 (br s, 1H), 7.00–7.06 (m, 2H),
7.15–7.41 (m, 9H), 7.53 (d, J = 7.2 Hz, 2H), 7.68 (d,
J = 7.6 Hz, 4H); 13C NMR (75 MHz, CDCl3) d 21.1, 37.6,
39.8, 41.3, 47.7, 60.7, 67.3, 120.4, 125.1, 125.6, 127.5,
128.1, 129.4, 129.8, 134.9, 141.8, 144.4, 156.2, 158.1,
173.9; HRMS calcd for C35H36N4O4 m/z 599.2634
(M??Na), found 599.2636.
(S,E)-Methyl-2-(3-(2-(((9H-fluoren-9-
yl)methoxy)carbonyl)ethyl)-2-benzylguanidino)-4-
methylpentanoate (2c) 368 mg
1H NMR (300 MHz, CDCl3) d 0.92 (d, J = 5.4 Hz, 6H),
1.45–1.71 (m, 3H), 2.52–2.63 (m, 2H), 2.79 (m, 2H), 2.97
(s, 2H), 3.31 (t, J = 4.2 Hz, 1H), 3.69 (s, 3H), 4.32 (t,
J = 2.9 Hz, 1H), 4.49 (d, J = 7.2 Hz, 2H), 5.69 (br s, 1H),
6.24 (s, br, 1H), 6.75 (br s, 1H), 7.09–7.81 (m, 13H), 13C
NMR (75 MHz, CDCl3) d 21.8, 22.5, 38.4, 41.1, 44.2,
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46.9, 50.8, 52.0, 54.3, 67.2, 119.8, 125.0, 126.8, 126.9,
127.6, 128.3, 129.2, 136.2, 141.1, 143.7, 154.3, 156.6,
170.7; HRMS calcd for C32H38N4O4 m/z 565.1615
(M??Na), found 565.1603.
(2S,3R)-Benzyl-2-(3-((S)-2-(benzyloxycarbonyl)-2-
phenylethyl)-2-(3-chlorophenyl)guanidino)-3-
methylpentanoate (2d) 406 mg
1H NMR (300 MHz, CDCl3) d 0.94 (t, J = 4.1 Hz, 3H),
0.98 (d, J = 4.4 Hz, 3H), 1.26–1.31 (m, 2H), 2.11–2.17
(m, 1H), 3.56 (d, J = 4.2 Hz, 2H), 3.67–3.72 (m, 1H),
4.75–4.80 (m, 1H), 5.12 (s, 4H), 5.34 (br s, 1H), 5.89 (br s,
1H), 6.56 (br s, 1H), 6.96–7.55 (m, 19H); 13C NMR
(75 MHz, CDCl3) d 16.5, 18.7, 28.8, 38.5, 48.6, 50.9, 62.3,
66.1, 125.0, 126.3, 127.0, 127.5, 127.6, 128.4, 140.6,
141.4, 155.6, 158.79, 171.2; HRMS calcd for C36H39-
ClN4O4 m/z 649.2558 (M
??Na), found 649.2556.
(S)-Methyl-2-(2-benzyl-3-((S)-2-(benzyloxycarbonyl)-3-
methylbutyl)guanidino) propanoate (2e) 304 mg
1H NMR (300 MHz, CDCl3) d 0.98 (d, J = 3.2 Hz, 6H),
1.39 (d, J = 5.6 Hz, 3H), 2.11–2.16 (m, 1H), 3.52–3.57
(m, 2H), 3.71 (s, 3H), 3.87-3.91 (m, 1H), 4.42–4.52 (m,
1H), 5.12 (s, 2H), 5.28 (s, 2H), 5.36 (br s, 1H), 5.92 (br s,
1H), 6.52 (br s, 1H), 7.25-7.46 (m, 10H); 13C NMR
(75 MHz, CDCl3) d 17.2, 18.7, 34.8, 42.4, 53.1, 53.3, 57.9,
61.3, 67.6, 128.3, 128.4, 128.7, 129.0, 136.5, 138.9, 156.6,
159.2, 172.0; HRMS calcd for C25H34N4O4 m/z 477.2478
(M??Na), found 477.2474.
(S)-Methyl-2-(3-((S)-2-(tert-butoxycarbonyl)-3-
phenylpropyl)-2-(4-methoxyphenyl)guanidino)-4-
methylpentanoate (2f) 362 mg
1H NMR (300 MHz, CDCl3) d 0.92 (d, J = 5.4 Hz, 6H),
1.45 (s, 9H), 1.47–1.71 (m, 3H), 2.79–2.88 (m, 2H),
2.00–2.20 (m, 1H), 3.51–3.56 (m, 2H), 3.63 (s, 3H), 3.74
(s, 3H), 3.85–4.00 (m, 1H), 4.80–4.95 (m, 1H), 5.24 (br s,
1H), 5.86 (br s, 1H), 6.57 (br s, 1H), 7.05–7.35 (m, 9H);
13C NMR (75 MHz, CDCl3) d 16.9, 19.3, 21.5, 29.7, 30.2,
43.6, 48.2, 50.1, 63.4, 65.2, 82.3, 128.1, 128.3, 128.7,
129.1, 136.3, 138.7, 155.1, 160.1, 172.2; HRMS calcd for
C29H42N4O5 m/z 549.3053 (M
??Na), found 549.3050.
(S)-Methyl-2-(3-((S)-2-(((9H-fluoren-9-
yl)methoxy)carbonyl)propyl)-2-(3-
chlorophenyl)guanidino)-3-methylbutanoate (2 g) 337 mg
1H NMR (300 MHz, CDCl3) d 0.89 (d, J = 3.7 Hz, 6H),
1.17 (d, J = 6.4 Hz, 3H), 2.12–2.20 (m, 1H), 2.41 (d,
J = 4.8 Hz, 1H), 2.82 (d, J = 7.1 Hz, 1H), 2.89 (d,
J = 11.2 Hz, 1H), 3.52 (s, 3H), 3.85–3.92 (m, 1H), 4.51 (t,
J = 6.6 Hz, 1H), 4.81 (d, J = 5.6 Hz, 2H), 6.12 (br s, 1H),
6.93 (br s, 1H), 7.12–7.75 (m, 12H); 13C NMR (75 MHz,
CDCl3) d 18.0, 18.9, 30.9, 42.7, 46.9, 49.4, 55.4, 57.9,
66.6, 119.7, 124.9, 126.8, 127.5, 128.0, 128.3, 135.4,
141.0, 143.6, 143.7, 153.9, 156.6, 170.1; ES-MS calcd for
C31H35ClN4O4 m/z 586.09 (M
??Na), found 586.07.
(S,E)-Methyl-2-(3-(2-(benzyloxycarbonyl)ethyl)-2-p-
tolylguanidino)-4-methylpentanoate (2 h) 295 mg
1H NMR (300 MHz, CDCl3) d 0.91 (d, J = 3.8 Hz, 6H),
1.15–1.22 (m, 2H), 1.71–1.83 (m, 1H), 2.91-3.06 (m, 2H),
3.18–3.23 (m, 2H), 3.61 (s, 3H), 3.96–4.02 (m, 1H), 5.04
Scheme 2 Possible reaction pathway for the synthesis of Na-protected N,N0,N00-trisubstituted guanidinopeptide mimics from thioureidopeptide
X = Me or Bzl moiety; Pg = Fmoc, Cbz or Boc group.
Scheme 1 Synthesis of Na-protected N,N0,N00-trisubstituted guani-
dinopeptide mimics 2a-i
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Table 1 List of Na-urethane protected N,N0,N00-trisubstituted guanidinopeptide mimics 2a–i
Entry Amine (R2) Na-protected trisubstituted guanidinopeptide mimics (2) Mp (oC) Yield (%)
1
2a
112–114 61
2
2b
131–135 66
3
2c
136–137 68
4
2d
Gum 65
5
2e
Gum 67
6
2f
Gum 69
7
2g
158–159 60
8
2h
Gum 65
9
2i
Gum 59
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(s, 2H), 5.92 (br s, 1H), 6.51 (br s, 1H), 7.01-7.29 (m, 5H);
13C NMR (75 MHz, CDC3) d 23.2, 23.5, 34.23, 37.9, 41.2,
42.7, 51.1, 58.4, 67.1, 128.2, 128.5, 129.0, 129.2, 138.4,
140.6, 156.4, 159.8, 170.0; HRMS calcd for C25H34N4O4
m/z 477.2478 (M??Na), found 477.2476.
(S)-Methyl-2-(2-benzyl-3-((S)-2-(tert-butoxycarbonyl)-3-
phenylpropyl) guanidino)propanoate (2i) 276 mg
1H NMR (300 MHz, CDCl3) d 1.24 (d, J = 3.6 Hz, 3H),
1.43 (s, 9H), 2.74 (d, J = 4.0 Hz, 2H), 3.41–3.46 (m, 2H),
3.62 (s, 3H), 3.72–3.79 (m, 1H), 3.98–4.02 (m, 1H), 4.93
(s, 2H), 5.26 (br s, 1H), 6.01 (br s, 1H), 6.89 (br s, 1H),
7.07–7.23 (m, 10H); 13C NMR (75 MHz, CDCl3) d 13.9,
29.5, 33.6, 38.7, 47.3, 53.3, 60.7, 66.6, 80.3, 126.6, 127.6,
127.9, 128.3, 128.5, 129.0, 136.1, 136.9, 156.2, 159.3,
172.5; HRMS calcd for C26H36N4O4 m/z 491.2634
(M??Na), found 491.2631.
(9H-Fluoren-9-yl)methyl-(S)-1-(2-benzyl-3-((S)-1-
phenylethyl)guanidino)-3-phenylpropan-2-ylcarbamate
(2j) 376 mg
1H NMR (300 MHz, CDCl3) d 1.48 (d, J = 6.0 Hz, 3H),
2.73–2.75 (m, 2H), 3.48–3.51 (m, 2H), 3.66–3.69 (m, 1H),
3.85–3.89 (m, 1H), 4.12 (t, J = 3.8 Hz, 1H), 4.24 (d,
J = 3.6 Hz, 2H), 5.02 (s, 2H), 5.20 (br s, 1H), 5.92 (br s,
1H), 6.58 (br s, 1H), 7.01–7.49 (m, 23H); 13C NMR
(75 MHz, CDCl3) d 22.8, 38.5, 42.8, 45.8, 47.2, 52.3, 53.9,
66.8, 126.8, 127.2, 127.7, 128.2, 128.5, 128.6, 128.9,
129.0, 136.2, 136.6, 139.8, 156.9, 159.8; HRMS calcd for
C40H40N4O2 m/z 631.3049 (M
??Na), found 631.3051.
Results and Discussion
Initially, a test reaction was carried out by taking Cbz-Val-
wCH2-NH-C(S)-NH-Ala-OMe as thiourea component in
the presence of HgCl2 and benzyl amine. The reaction was
performed in the presence of triethylamine (TEA) at 0 C
to r.t under mild conditions. The reaction afforded the
desired trisubstituted guanidinopeptide, Cbz-Val-wCH2-
NH-C(NBn)-NH-Ala-OMe in good yield (67 %). During
the course of the reaction, an aliquot of the reaction mix-
ture was taken and analysed by IR. A strong absorption
peak in the region 2118–2138 cm-1 corresponding to
–N=C=N– stretch of the carbodiimide formed in situ by the
desulphurization of thioureidopeptide was noticed. The
conditions were then optimized with respect to the equiv-
alence of amine and HgCl2 required (Scheme 1). It was
found that 1.2 equiv. of amine and 0.35 equiv. of HgCl2
afforded the product in good yields. The product was
isolated after a simple work up and characterized by mass,
1H and 13C NMR analyses.
Zhang and Fan (2005) reported that the Fmoc protected
amino acid derived thiourea prepared by the reaction of
Fmoc protected vicinal diamine with Pbf-NCS on desul-
phurization in presence of EDCl resulted in cyclic guani-
dine as major product. The reaction was mediated through
the highly electrophilic carbodiimide (attached to Pbf)
which can trap adjacent weakly nucleophilic carbamate
nitrogen and undergoes intramolecular cyclization result-
ing in cyclic guanidine. However, in case of thiourei-
dopeptides due to the lack of such electron withdrawing
groups, the formed carbodiimide is comparatively less
reactive than the aryl counterparts. To our delight
intramolecular cyclization did not occur (ES-MS analysis
of the obtained crude product revealed only the presence of
trisubstituted guanidine and not the cyclized product), as
the nucleophilicity of carbamate nitrogen is inefficient for
addition to the less electrophilic carbodiimide. During the
course of reaction, the amine component will preferably
added to the carbodiimide in presence of base rather than
the carbamate nitrogen, as illustrated in Scheme 2.
The generality of the protocol was further exemplified
with a series of N-protected thioureidopeptides with dif-
ferent urethane protections such as Fmoc, Cbz and Boc,
which on guanidinylation employing seven different aro-
matic amines with or without other substitutions resulted in
trisubstituted guanidinopeptides in good yields (Table 1).
Further, the structural analyses of the products were carried
out through mass, 1H and 13C NMR spectroscopic analyses.
Also the protocol employed for the synthesis of title
molecules was proved to be racemisation free as evidenced
by the HPLC analysis of diastereomeric trisubstituted
guanidinopeptides, 2j and 2k obtained by the reaction of
corresponding chiral thioureidopeptides, Fmoc-Phe-
w[CH2NC(S)NH]-(S)-1-phenethylamine and Fmoc-Phe-
w[CH2NC(S)NH]-(R)-1-phenethylamine with benzy-
lamine, which exhibited Rf values 12.4 and 12.7 min
respectively. Whereas the equimolar mixture of 2j and 2k
exhibited the Rf values 12.2 and 12.5 min, which indicated
the presence of two different isomers.
Conclusion
In conclusion herein we described a simple and mild pro-
tocol for an efficient one pot transformation of thiourei-
dopeptides into hitherto unreported class of Na-urethane
protected N,N0,N00-trisubstituted guanidinopeptide mimics
in relatively good yields employing HgCl2 as a desul-
phurizing agent. The protocol is simple and the reaction
conditions employed were mild in affording products in
moderate to good yields.
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